Mili(Norgestimate-Ethinyl Estradiol)
AUROPHARMA.NS
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Aurobindo Pharma Limited
$144K
Medicare cost, 2024
$144K
Medicare cost, 2024
Medicare drug plans spent $143,629 on Mili (norgestimate-ethinyl estradiol) in 2024, for 6,349 prescriptions and refills filled by 1,997 patients. Spending fell 23% from 2023 to 2024. Indiana accounts for the most spending ($12,165, 8% of the total). It is made by Aurobindo Pharma Limited (AUROPHARMA.NS).
Medicare cost, 2024
$144K
-23.1% from 2023
Prescriptions
6,349
$22.62 per claim
Patients
1,997
2,237 prescribers
Total spending, 2024
$144K
$71.92 per patient
Questions and answers
How much does Medicare spend on Mili?
Medicare prescription drug plans paid $144K for Mili in 2024, for 6,349 prescriptions and refills to 1,997 patients (down 23.1% from 2023). The average cost per claim was $22.62.
Which state spends the most on Mili?
Indiana had the highest Medicare cost for Mili in 2024: $12K for 599 claims, followed by Florida ($11K).
Who prescribes Mili the most?
Angela H Grimaldo, nurse practitioner in Dallas, TX, had the highest Medicare cost for Mili in 2024: 25 claims costing $717.
Who makes Mili?
Mili is made by Aurobindo Pharma Limited (AUROPHARMA.NS), listed in the Medicare spending data as Aurobindo Pharm.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Mili was $144K in 2024, after a high of $211K in 2021.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Mili, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Angela H Grimaldo Dallas, TX | Nurse Practitioner | 25 | Under 11 | $717 |
| 1508856170 | Internal Medicine | 20 | Under 11 | $532 |
| Sana Hira Chicago, IL | Physician Assistant | 17 | Under 11 | $465 |
| Kavitha Srinivasan Glenview, IL | Internal Medicine | 15 | Under 11 | $424 |
| Mary Wildeman Nashville, TN | Nurse Practitioner | 13 | Under 11 | $352 |
| Asma M Syeda West Mifflin, PA | Family Practice | 12 | Under 11 | $334 |
| Elisabeth Cooper Redding, CA | Physician Assistant | 12 | Under 11 | $320 |
| James E Thompson Bedford, VA | Family Practice | 11 | Under 11 | $311 |
| Jessica Roberts Antioch, CA | Family Practice | 13 | Under 11 | $302 |
| Kimberly D Massey Tifton, GA | Nurse Practitioner | 13 | Under 11 | $296 |
| Jacob F Cogen Pleasantville, NJ | Family Practice | 11 | Under 11 | $279 |
| Christopher R Wainwright Jacksonville, FL | Family Practice | 13 | Under 11 | $259 |
| Kimberly A Hindi Montgomery, AL | Nurse Practitioner | 13 | Under 11 | $259 |
| Carol A Ketchen Spartanburg, SC | Obstetrics & Gynecology | 13 | Under 11 | $259 |
| Julie A Raekes Richland, WA | Internal Medicine | 11 | Under 11 | $256 |
| Sailaja M Blackmon Fort Wayne, IN | Obstetrics & Gynecology | 13 | Under 11 | $255 |
| Kristen Green Lincoln, IL | Obstetrics & Gynecology | 13 | Under 11 | $255 |
| Wayne Blevins Jr. Carlinville, IL | Emergency Medicine | 13 | Under 11 | $255 |
| Heather Doolittle Auburn, IN | Nurse Practitioner | 12 | Under 11 | $252 |
| Herndon M Jeansonne II Cottonport, LA | Nurse Practitioner | 13 | Under 11 | $246 |
| Steven H Lee Austell, GA | Obstetrics & Gynecology | 13 | Under 11 | $237 |
| Aimee Diaz Tamarac, FL | Nurse Practitioner | 13 | Under 11 | $233 |
| James P McDermott Manahawkin, NJ | Obstetrics & Gynecology | 16 | Under 11 | $227 |
| Jessica E Horvath - Matthews Sewell, NJ | Family Practice | 13 | Under 11 | $206 |
| Stacey L Walter Mc Arthur, OH | Family Practice | 11 | Under 11 | $201 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 2,265 | 6,151 | 2,047 | $199K |
| 2023 | 2,270 | 6,426 | 2,040 | $187K |
| 2024 | 2,237 | 6,349 | 1,997 | $144K |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Aurobindo Pharm | 6,349 | $144K |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 6
- RxNorm concept IDs
- 1800499, 240128, 748797, 749860
- Application numbers
- ANDA205449
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 4,621 side-effect reports named norgestimate and ethinyl estradiol, the active ingredient of Mili (reports from 2004 on). 1,865 of them (40.4%) were serious, 43 named a death and 676 named a hospital stay. The reactions named most often were nausea, headache and drug ineffective. 1,207 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
4,621
187 in 2025 (-31.3% from 2024)
Serious
40.4%
1,865 reports
Deaths named
43
0.9% of reports
Hospital stays
676
14.6% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Mili?
4,621 reports from 2004 through September 2026 named norgestimate and ethinyl estradiol, the active ingredient of Mili. 1,865 of them (40.4%) were serious, 43 named a death and 676 named a hospital stay.
What are the most reported side effects of Mili?
422 reports named nausea, the reaction named most often, followed by headache (284) and drug ineffective (269). In the last 5 years the reaction named most often was nausea (104 reports). A report can name several reactions.
How many side-effect reports named Mili in 2025?
187 reports were received in 2025 (-31.3% from 2024). 2026 so far: 171 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Mili caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Mili caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with norgestimate and ethinyl estradiol: Sprintec, Tri-Sprintec, Estarylla, Tri-Lo-Mili, Tri-Estarylla, Mono-Linyah, Tri-Lo-Marzia, Tri-Linyah
- Makers on the stock market:
AUROPHARMA.NS
LUPIN.NS
TEVA·AUROPHARMA.NS drug pipeline - Drug approvals (13 approvals on file for norgestimate and ethinyl estradiol) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (norgestimate and ethinyl estradiol) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.